Mirum Pharmaceuticals, Inc. (MIRM) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.52B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-674.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in Capital, Common StockUSD $1.70B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-28.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $981.88M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $351.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $5.00K; Additional Paid in Capital, Common StockUSD $953.82M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $37.00K.
Mirum Pharmaceuticals, Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Treasury Stock, Common, Shares shares |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $6.00K | $1.52B | $-674.00K | $-1.52B | $-10.42M | 3 month · $30.61M | (m) |
| 2026-03-31 | $0.00 | $6.00K | $1.70B | $-28.00K | $-1.46B | $242.49M | 3 month · $22.34M | (m) |
| 2025-12-31 | $0.00 | $5.00K | $981.88M | $351.00K | $-667.54M | $314.69M | 12 month · $71.52M | (m) |
| 2025-09-30 | $0.00 | $5.00K | $953.82M | $37.00K | $-661.81M | $292.05M | 3 month · $18.19M | (m) |
| 2025-06-30 | $0.00 | $5.00K | $919.52M | $352.00K | $-664.72M | $255.16M | 3 month · $18.46M | (m) |
| 2025-03-31 | $0.00 | $5.00K | $892.37M | $-258.00K | $-658.86M | $233.26M | 3 month · $15.81M | (m) |
| 2024-12-31 | $0.00 | $5.00K | $870.19M | $-373.00K | $-644.18M | $225.64M | 12 month · $49.23M | (m) |
| 2024-09-30 | $0.00 | $5.00K | $851.49M | $920.00K | $-620.39M | $232.02M | 3 month · $12.01M | (m) |
| 2024-06-30 | $0.00 | $5.00K | $835.62M | $-477.00K | $-606.16M | $228.99M | 3 month · $12.20M | (m) |
| 2024-03-31 | $0.00 | $5.00K | $816.13M | $-13.00K | $-581.52M | $234.60M | 3 month · $11.66M | (m) |
| 2023-12-31 | $0.00 | $5.00K | $803.26M | $1.64M | $-556.24M | $248.67M | 12 month · $35.84M | (m) |
| 2023-09-30 | $0.00 | $5.00K | $791.11M | $-1.46M | $-520.58M | $269.08M | 3 month · $8.59M | (m) |
| 2023-06-30 | $0.00 | $4.00K | $575.52M | $76.00K | $-496.99M | $78.61M | 3 month · $8.56M | (m) |
| 2023-03-31 | $0.00 | $4.00K | $563.96M | $136.00K | $-422.95M | $141.15M | 3 month · $8.73M | (m) |
| 2022-12-31 | $0.00 | $4.00K | $535.07M | $-217.00K | $-392.82M | $142.04M | 12 month · $27.45M | (m) |
| 2022-09-30 | $0.00 | $4.00K | $526.10M | $-413.00K | $-356.39M | $169.30M | 3 month · $7.07M | (m) |
| 2022-06-30 | $0.00 | $3.00K | $431.57M | $-202.00K | $-320.69M | $110.69M | 3 month · $6.82M | (m) |
| 2022-03-31 | $0.00 | $3.00K | $402.82M | $-131.00K | $-293.76M | $108.93M | 3 month · $6.56M | (m) |
| 2021-12-31 | $0.00 | $3.00K | $377.40M | $-35.00K | $-257.16M | $120.21M | 12 month · $23.09M | (m) |
| 2021-09-30 | $0.00 | $3.00K | $371.10M | $-6.00K | $-314.70M | $56.40M | 3 month · $7.42M | (m) |
| 2021-06-30 | (m) | $3.00K | $363.34M | $-13.00K | $-267.60M | $95.74M | 3 month · $4.82M | (m) |
| 2021-03-31 | $0.00 | $3.00K | $357.58M | $0.00 | $-223.70M | $133.88M | 3 month · $5.29M | (m) |
| 2020-12-31 | $0.00 | $3.00K | $345.18M | $83.00K | $-173.17M | $172.09M | 12 month · $12.55M | (m) |
| 2020-09-30 | $0.00 | $3.00K | $256.05M | $172.00K | $-135.97M | $120.25M | 3 month · $3.43M | (m) |
| 2020-06-30 | $0.00 | $3.00K | $250.35M | $318.00K | $-114.46M | $136.21M | 3 month · $2.97M | (m) |
| 2020-03-31 | $0.00 | $3.00K | $247.35M | $-24.00K | $-91.21M | $156.12M | 3 month · $2.57M | (m) |
| 2019-12-31 | $0.00 | $2.00K | $200.12M | $129.00K | $-69.90M | $130.35M | 12 month · $6.07M | (m) |
| 2019-09-30 | $0.00 | $2.00K | $198.05M | $98.00K | $-51.95M | $146.20M | 3 month · $2.14M | (m) |
| 2019-06-30 | (m) | $1.00K | $1.89M | $28.00K | $-36.86M | $-34.94M | 3 month · $1.64M | 456.44K |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-23.05M | 3 month · $218.00K | (m) |
| 2018-12-31 | (m) | $1.00K | $34.00K | (m) | $-17.35M | $-17.31M | 8 month · $34.00K | 550.78K |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | $-76.00K | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | $-10.00K | (m) | (m) |
| 2018-05-02 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |